| __timestamp | Bristol-Myers Squibb Company | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 8185000 |
| Thursday, January 1, 2015 | 5001000000 | 8871000 |
| Friday, January 1, 2016 | 5002000000 | 9645000 |
| Sunday, January 1, 2017 | 4849000000 | 12387000 |
| Monday, January 1, 2018 | 4551000000 | 14381000 |
| Tuesday, January 1, 2019 | 4871000000 | 19238000 |
| Wednesday, January 1, 2020 | 7661000000 | 17425000 |
| Friday, January 1, 2021 | 7690000000 | 23040000 |
| Saturday, January 1, 2022 | 7814000000 | 25116000 |
| Sunday, January 1, 2023 | 7772000000 | 51953000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the world of pharmaceuticals, effective cost management is crucial. Bristol-Myers Squibb Company (BMY) and CymaBay Therapeutics, Inc. (CBAY) offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, BMY has consistently managed higher SG&A expenses, peaking at approximately $7.8 billion in 2022, a 37% increase from 2014. In contrast, CBAY's SG&A expenses, while significantly lower, have shown a remarkable growth trajectory, surging over 500% from 2014 to 2023. This disparity highlights the differing scales and strategies of these companies. While BMY's expenses reflect its expansive operations, CBAY's growth in SG&A spending underscores its aggressive expansion efforts. As the pharmaceutical landscape evolves, these insights into cost management strategies offer valuable lessons for industry stakeholders.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE